Metastatic Colorectal Cancer. Real-World Data Analysis.

Completed

• Conditions: Metastatic Colorectal Cancer

• Registration Number: NCT04757311
• Lead Sponsor: Istanbul Medeniyet University

Brief Summary

The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis

Detailed Description

In this study, with the given rationale is to reveal treatment approaches, survival data, side effect profile and their management in our country in RAS WT mCRC patients by means of the real-world data collection.

Study Timeline

• Study Start: 2020-08-01
• Study First Submitted: 2020-08-30
• Study First Submitted QC: 2021-02-16
• Study First Posted: 2021-02-17
• Primary Completion: 2021-04-30
• Status Verified: 2021-10
• Study Completion: 2021-10-01
• Last Update Submitted: 2021-10-25
• Last Update Posted: 2021-10-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1750

Inclusion Criteria

1. Patients who have been histologically diagnosed with mCRC
2. Patients over the age of 18
3. Patients receiving at least a cycle systemic treatment for metastatic disease
4. RAS wild type patients
5. Patients who has demographic, histopathological and clinical information

Exclusion Criteria

1. Patients diagnosed as mCRC but only referred to BSC
2. Patients with RAS mutation
3. Patients who were included in any clinical trial except standard treatments during their treatment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of use anti-EGFR agents	throughout of treatment, 3 years	The anti-EGFR agent selection
Progression Free Survival (PFS)	3 years treatment	PFS three years after initiation of treatment with anti-EGFR agents

Secondary Outcome Measures

Name	Time	Method
Advers events	throughout of treatment, 3 years	Advers event of anti EGFR is defined as any untoward or unfavourable medical occurrence, including any abnormal sign, symptom, or disease, temporally associated with the patient's participation. The CTCAE v.4.0 will use in this research.

Trial Locations

Locations (1)

Istanbul Medeniyet University Hospital; 🇹🇷 Istanbul, Turkey